Evidence map›Paper›PMID 36348317›Full record

ArticleBMC cancer2022

Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes.

Koichi Sato, Hiroaki Akamatsu, Yasuhiro Koh, Koichi Ogawa, Shun-Ichi Isa, Masahiko Ando, Akihiro Tamiya, Akihito Kubo, Chiyoe Kitagawa, Tomoya Kawaguchi and 1 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Mechanisms and current advances in treatingChinese medical journal pulmonary and critical care medicine · 2025
    Review
  3. Article
  4. Article
  5. Targeting KRASDrugs · 2024
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Koichi SatoInternal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan.
Hiroaki AkamatsuInternal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan. hiroakiakamatsu@gmail.com.
Yasuhiro KohInternal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan. ykoh@wakayama-med.ac.jp.
Koichi OgawaDepartment of Respiratory Medicine, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-cho, Abeno-ku, Osaka-shi, Osaka, 545-8585, Japan.
Shun-Ichi IsaClinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai-shi, Osaka, 591-8555, Japan.
Masahiko AndoDepartment of Advanced Medicine, Nagoya University Hospital, 65 Tsurumai-cho, Showa-ku, Nagoya-shi, Aichi, 466-8560, Japan.
Akihiro TamiyaInternal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai-shi, Osaka, 591-8555, Japan.
Akihito KuboMedical Oncology, Oncology Center, Aichi Medical University School of Medicine, 1-1 Yazakokarimata, Nagakute-shi, Aichi, 480-1195, Japan.
Chiyoe KitagawaMedical Oncology and Respiratory Medicine, National Hospital Organization Nagoya Medical Center, 4-1-1 Sannomaru, Naka-ku, Nagoya-shi, Aichi, 460-0001, Japan.
Tomoya KawaguchiDepartment of Respiratory Medicine, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-cho, Abeno-ku, Osaka-shi, Osaka, 545-8585, Japan.
Nobuyuki YamamotoInternal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan.
Wakayama Medical University · JPNational Kinki Chuo Hospital for Chest Disease · JPOsaka Metropolitan UniversityAichi Medical University · JPNagoya Medical Center · JPNagoya University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKRAS-mutated non-small cell lung cancer (NSCLC) accounts for 23-35% and 13-20% of all NSCLCs in white patients and East Asians, respectively, and is therefore regarded as a major therapeutic target. However, its epidemiology and clinical characteristics have not been fully elucidated because of its wide variety of mutational subtypes. Here, we focused on two distinct base substitution types: transversion mutations and transition mutations, as well as their association with environmental factors and clinical outcome.

methodsDataset from the Japan Molecular Epidemiology Study, which is a prospective, multicenter, and molecular study epidemiology cohort study involving 957 NSCLC patients who underwent surgery, was used for this study. Questionnaire-based detailed information on clinical background and lifestyles was also used to assess their association with mutational subtypes. Somatic mutations in 72 cancer-related genes were analyzed by next-generation sequencing, and KRAS mutations were classified into three categories: transversions (G > C or G > T; G12A, G12C, G12R, G12V), transitions (G > A; G12D, G12S, G13D), and wild-type (WT). Clinical correlations between these subtypes have been investigated, and recurrence-free survival (RFS) and overall survival (OS) were evaluated.

resultsOf the 957 patients, KRAS mutations were detected in 80 (8.4%). Of these, 61 were transversions and 19 were transitions mutations. Both pack-years of smoking and smoking duration had significant positive correlation with the occurrence of transversion mutations (p = 0.03 and < 0.01, respectively). Notably, transitions showed an inverse correlation with vegetable intake (p = 0.01). Patients with KRAS transitions had the shortest RFS and OS compared to KRAS transversions and WT. Multivariate analysis revealed that KRAS transitions, along with age and stage, were significant predictors of shorter RFS and OS (HR 2.15, p = 0.01; and HR 2.84, p < 0.01, respectively).

conclusionsSmoking exposure positively correlated with transversions occurrence in a dose-dependent manner. However, vegetable intake negatively correlated with transitions. Overall, KRAS transition mutations are significantly poor prognostic factors among resected NSCLC patients.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsCohort StudiesHumansMutationProspective StudiesProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras ProteinsKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras ProteinsEnvironmental factorsKRASNon-small cell lung cancerSmokingTransitionTransversion

Identifiers

PMID36348317
PMCPMC9641926
OpenAlexW4308590401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.